Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving?

Onconetix Inc. (NASDAQ: ONCO ) shares soared 23.65% to $0.38 in after-hours trading on Monday. The Ohio-based biotechnology company reversed a steep 18.26% regular session decline, closing the stock at $0.31, according to Benzinga Pro data. Clinical Validation On May 13, Onconetix reported first-quarter 2026 operational progress from its fully-owned Swiss subsidiary, Proteomedix AG , developer of Proclarix, a CE-IVD certified blood test designed to identify clinically significant prostate cancer in combination with prostate-specific antigen (PSA) testing. Prostate cancer is the most commonly diagnosed cancer in men in most countries around the world and places a significant burden on patients and healthcare systems. A National Institutes of Health 2019 report found that in 2018, over 1 million new cases of prostate cancer were reported globally, accounting for 7.1% of all cancers diagnosed in men. According to the ... Full story available on Benzinga.com